Newsroom

October 2016

• Press release Oct 25, 2016

  Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster

  Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…
• Press release Oct 25, 2016

  Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels

  Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa…
• Press release Oct 17, 2016

  Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting

  Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
• 
  Story Oct 13, 2016 Discovery

  The Evolution of a Scientist

  A middle school student curious about science grows into a college-bound scientist.

• 
  Story Oct 13, 2016 Discovery

  Women in Science: Tania Small

  Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series

• 
  Story Oct 13, 2016 Access to Healthcare

  New Orbis Flying Eye Hospital helps fight blindness in China

  During a three-week maiden voyage to the northern city of Shenyang, the plane's medical volunteers treated 124 patients and provided hands-on surgical training to 18 local doctors.

• Press release Oct 09, 2016

  Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

  Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
• Press release Oct 08, 2016

  Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up

  Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
• Press release Oct 08, 2016

  Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

  LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
• 
  Story Oct 05, 2016 Discovery

  Chan Zuckerberg Initiative friends Novartis scientist in mission to conquer disease

  Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub

• 
  Story Oct 03, 2016 From Our Labs

  Improving science communication in 3 easy steps

• 
  Story Oct 03, 2016 Patient Perspectives

  Digital health: providing opportunities for advocacy groups and a community for patients

  Learn about how digital is changing the face of patient advocacy.